TAM biomarkers, such as CD68, CD163, and TREM2, among others, are associated with clinical outcomes in various solid tumors, whereas CD68 is associated with a good prognosis in colorectal cancer but typically reflects a poor outcome in other cancers (75). This evidence concerns the gene CD68 and colorectal cancer.